Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug Applications for Combination Drug Medicated Feeds Containing an Arsenical Drug; Correction, 17859-17860 [2014-06994]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 61 / Monday, March 31, 2014 / Rules and Regulations
(2) Pratt & Whitney Engine Manual, P/N
1A6231, (PW2000) and P/N 1B2412 (F117),
Chapter 72–41–00, Inspection/Check-02,
(Task 72–41–00–230–002) and Chapter 72–
52–00, Inspection/Check-02 (Task 72–52–00–
230–000), which are not incorporated by
reference in this AD, can be obtained from
Pratt & Whitney, using the contact
information in paragraph (l)(3) of this AD.
(l) Material Incorporated by Reference
(1) The Director of the Federal Register
approved the incorporation by reference
(IBR) of the service information listed in this
paragraph under 5 U.S.C. 552(a) and 1 CFR
part 51.
(2) You must use this service information
as applicable to do the actions required by
this AD, unless the AD specifies otherwise.
(i) Pratt & Whitney Service Bulletin No.
PW2000 72–763, Revision 1, dated August
30, 2013.
(ii) Reserved
(3) For PW service information identified
in this AD, contact Pratt & Whitney, 400
Main St., East Hartford, CT 06108; phone:
860–565–8770; fax: 860–565–4503.
(4) You may view this service information
at the FAA, Engine & Propeller Directorate,
12 New England Executive Park, Burlington,
MA. For information on the availability of
this material at the FAA, call 781–238–7125.
(5) You may view this service information
at the National Archives and Records
Administration (NARA). For information on
the availability of this material at NARA, call
202–741–6030, or go to: https://
www.archives.gov/federal-register/cfr/ibrlocations.html.
Issued in Burlington, Massachusetts, on
March 6, 2014.
Colleen M. D’Alessandro,
Assistant Directorate Manager, Engine &
Propeller Directorate, Aircraft Certification
Service.
[FR Doc. 2014–06953 Filed 3–28–14; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF TRANSPORTATION
Federal Aviation Administration
14 CFR Part 71
[Docket No. FAA–2013–0079; Airspace
Docket No. 09–AWA–4]
RIN 2120–AA66
Amendment to Class B Airspace Area;
Detroit, MI
Federal Aviation
Administration (FAA), DOT.
ACTION: Final rule; correction.
emcdonald on DSK67QTVN1PROD with RULES
AGENCY:
This action corrects a final
rule published in the Federal Register
January 21, 2014. In that rule, the shared
boundary between the Detroit Class B
airspace Area A and Area B subareas
did not match, as originally intended, in
the regulatory text descriptions. This
SUMMARY:
VerDate Mar<15>2010
16:18 Mar 28, 2014
Jkt 232001
correction is necessary to close the
unintended gap between subareas
created by the boundary error and to
ensure the accuracy of the charted
Detroit Class B airspace area.
DATES: Effective Date: 0901 UTC, April
3, 2014. The Director of the Federal
Register approves this incorporation by
reference action under 3 CFR part 51,
subject to the annual revision of FAA
Order 7400.9 and publication of
conforming amendments.
FOR FURTHER INFORMATION CONTACT:
Colby Abbott, Airspace Policy and
Regulations Group, Office of Airspace
Services, Mission Support, Federal
Aviation Administration, 800
Independence Avenue SW.,
Washington, DC 20591; telephone: (202)
267–8783.
SUPPLEMENTARY INFORMATION:
History
Correction to Final Rule
Accordingly, pursuant to the
authority delegated to me, in the
Federal Register of January 21, 2014,
the text on page 3312, column 2, line 47,
is corrected to read:
Frm 00011
[Amended]
AGL MI B Detroit, MI [Corrected]
For Area A, between the words
‘‘Airport;’’ and ‘‘thence’’, add the
following: ‘‘thence northeast to the
intersection of the DXO VOR/DME 354°
radial and the Detroit Willow Run
Airport 047° bearing:’’.
Issued in Washington, DC, on March 24,
2014.
Ellen Crum,
Acting Manager, Airspace Policy and
Regulations Group.
[FR Doc. 2014–06959 Filed 3–28–14; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 558
On January 21, 2014, a final rule for
FAA Docket No. FAA–2012–0661,
Airspace Docket No. 09–AWA–4, was
published in the Federal Register (79
FR 3305) to amend the Detroit Class B
airspace area. The Detroit Class B
airspace area was modified to contain
aircraft conducting published
instrument procedures at Detroit
Metropolitan Wayne County Airport
(DTW) within Class B airspace, enhance
safety, improve the flow of air traffic,
and reduce the potential for midair
collisions in the DTW terminal area,
while accommodating the concerns of
all airspace users.
Subsequent to publication of the rule,
the FAA determined the boundary
segment described in Area A, from lat.
42°17′18″ N., long. 83°27′27″ W. on the
4.4-mile radius of the Detroit Willow
Run Airport to lat. 42°20′47″ N., long.
83°22′12″ W. on the 8-mile arc of the
DXO VOR/DME, and the boundary
segment described in Area B, from the
intersection of the DXO VOR/DME 354°
radial and the Detroit Willow Run
Airport 047° bearing to lat. 42°20′47″ N.,
long. 83°22′12″ W., did not align as
intended and contained a gap between
the two adjacent subareas. The FAA is
correcting this minor error by adding
the geographic point defined by the
intersection of the DXO VOR/DME 354°
radial and the Detroit Willow Run
Airport 047° bearing in the Area A
description to remove the gap.
PO 00000
§ 71.1
17859
Fmt 4700
Sfmt 4700
[Docket No. FDA–2014–N–0002]
Zoetis Inc., et al.; Withdrawal of
Approval of New Animal Drug
Applications for Combination Drug
Medicated Feeds Containing an
Arsenical Drug; Correction
AGENCY:
Food and Drug Administration,
HHS.
Final rule; correcting
amendments.
ACTION:
The Food and Drug
Administration (FDA) is correcting a
document amending the animal drug
regulations to reflect the withdrawal of
approval of new animal drug
applications (NADAs) that appeared in
the Federal Register of February 27,
2014 (79 FR 10976). That document
listed an NADA for which a withdrawal
of approval (WOA) was not intended
and failed to remove all conditions of
use associated with the withdrawn
NADAs. This correction is being made
to improve the accuracy of the animal
drug regulations.
DATES: This correction is effective
March 31, 2014.
FOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary
Medicine (HFV–6), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–9019,
george.haibel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
correcting a document amending the
animal drug regulations to reflect the
WOA of NADAs that appeared in the
Federal Register of February 27, 2014
(79 FR 10976). That document listed an
NADA for which a WOA was not
intended and failed to remove all
SUMMARY:
E:\FR\FM\31MRR1.SGM
31MRR1
17860
Federal Register / Vol. 79, No. 61 / Monday, March 31, 2014 / Rules and Regulations
conditions of use associated with the
withdrawn NADAs. This correction is
being made to improve the accuracy of
the animal drug regulations.
In the preamble in rule FR Doc. 2014–
02617 published on February 27, 2014
(79 FR 10976), make the following
corrections:
On page 10976, in the second column,
in the 4th line of the ‘‘SUMMARY’’
section, remove ‘‘69’’ and replace with
‘‘68’’.
On page 10977, appearing near the
end of the page, ‘‘Huvepharma AD, 5th
Floor, 3A Nikolay Haitov Str., 1113
Sofia, Bulgaria, has requested that FDA
withdraw approval of the following 16
NADAs and 8 ANADAs’’, is corrected to
read ‘‘Huvepharma AD, 5th Floor, 3A
Nikolay Haitov Str., 1113 Sofia,
Bulgaria, has requested that FDA
withdraw approval of the following 15
NADAs and 8 ANADAs’’; and on the
same page in the table, the entry ‘‘013–
461 3–NITRO (roxarsone)/AMPROL
Plus (amprolium and ethopabate).’’ is
removed. This rule does not meet the
definition of ‘‘rule’’ in 5 U.S.C.
804(3)(A) because it is a rule of
‘‘particular applicability.’’ Therefore, it
is not subject to the congressional
review requirements in 5 U.S.C. 801–
808.
List of Subjects in 21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 558 is corrected by making the
following correcting amendments.
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
1. The authority citation for 21 CFR
part 558 continues to read as follows:
■
Authority: 21 U.S.C. 360b, 371.
§ 558.195
[Amended]
2. In § 558.195, remove paragraph
(e)(1)(vii).
■
§ 558.355
[Amended]
3. In § 558.355, remove and reserve
paragraph (b)(3).
■ 4. In § 558.635, revise paragraphs
(d)(4)(v), (d)(4)(vi), and (d)(4)(vii) to
read as follows:
emcdonald on DSK67QTVN1PROD with RULES
■
§ 558.635
*
Virginiamycin.
*
*
*
*
(d) * * *
(4) * * *
(v) Monensin as in § 558.355.
(vi) Salinomycin as in § 558.550.
(vii) Semduramicin as in § 558.555.
VerDate Mar<15>2010
16:18 Mar 28, 2014
Jkt 232001
Dated: March 25, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014–06994 Filed 3–28–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF THE TREASURY
Internal Revenue Service
26 CFR Part 31
[TD 9662]
RIN 1545–BJ31
Designation of Payor To Perform Acts
Required of an Employer
Internal Revenue Service (IRS),
Treasury.
ACTION: Final regulations.
AGENCY:
This document contains final
regulations under section 3504 of the
Internal Revenue Code (Code) providing
circumstances under which a person
(payor) is designated to perform the acts
required of an employer and is liable for
employment taxes with respect to wages
or compensation paid by the payor to
individuals performing services for the
payor’s client pursuant to a service
agreement between the payor and the
client.
SUMMARY:
Effective date: These final
regulations are effective on March 31,
2014.
Applicability date: For dates of
applicability, see § 31.3504–2(f) of these
regulations.
FOR FURTHER INFORMATION CONTACT:
Jeanne Royal Singley at (202) 317–6798
(not a toll-free number).
SUPPLEMENTARY INFORMATION:
DATES:
Background
This document contains amendments
to 26 CFR part 31 under section 3504 of
the Code. On January 29, 2013, Treasury
and the IRS published a notice of
proposed rulemaking (REG–102966–10,
78 FR 6056) (the proposed regulations)
in the Federal Register under section
3504 of the Code. Treasury and the IRS
received written and electronic
comments responding to the proposed
regulations. All comments were
considered and are available for public
inspection at https://
www.regulations.gov or upon request.
After consideration of all the public
comments, the proposed regulations are
adopted as amended by this Treasury
decision. The public comments and
revisions are discussed in this preamble.
PO 00000
Frm 00012
Fmt 4700
Sfmt 4700
Explanation of Provisions
Under section 3504, if a payor pays
wages or compensation to employees
who are employed by one or more
employers, the Secretary is authorized,
in accordance with regulations
prescribed by the Secretary, to designate
such payor to perform acts required of
employers under the Code. Section 3504
further provides that, except as
otherwise prescribed by the Secretary,
all provisions of law (including
penalties) applicable with respect to an
employer are applicable to the payor so
designated, but the employer for whom
the payor acts remains subject to the
provisions of law (including penalties)
applicable with respect to employers.
Accordingly, both an employer and the
payor designated in accordance with
regulations under section 3504 are liable
for the employment taxes on wages or
compensation paid by the payor.
The IRS has established
administrative procedures under which
a payor may request authorization on
Form 2678, Employer/Payer
Appointment of Agent, to file
employment tax returns and perform
other acts for the employer. The
proposed regulations provide rules
regarding the employment tax
obligations under certain three-party
arrangements in which a payor enters
into an agreement with the employer
(client) to perform the employment tax
obligations of the client with regard to
wages or compensation paid by the
payor to individuals performing services
for the client, but the payor does not use
the established IRS administrative
procedures to request authorization to
file employment tax returns and
performs other acts for the client.
Under the proposed regulations, a
payor is designated under section 3504
to perform the acts of an employer in
any case in which the payor enters into
a service agreement with a client. For
this purpose, the term service agreement
means a written or oral agreement
pursuant to which the payor (1) asserts
it is the employer (or ‘‘co-employer’’) of
individuals performing services for the
client, (2) pays wages or compensation
to the individuals for services the
individuals perform for the client, and
(3) assumes responsibility to collect,
report, and pay, or assumes liability for,
any employment taxes with respect to
the wages or compensation paid by the
payor to the individuals who perform
services for the client.
The proposed regulations also provide
exceptions to when a payor is
designated under section 3504 to
perform the acts of an employer even if
the payor has entered into an agreement
E:\FR\FM\31MRR1.SGM
31MRR1
]]>Agencies
[Federal Register Volume 79, Number 61 (Monday, March 31, 2014)]
[Rules and Regulations]
[Pages 17859-17860]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-06994]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 558
[Docket No. FDA-2014-N-0002]
Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug
Applications for Combination Drug Medicated Feeds Containing an
Arsenical Drug; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; correcting amendments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a
document amending the animal drug regulations to reflect the withdrawal
of approval of new animal drug applications (NADAs) that appeared in
the Federal Register of February 27, 2014 (79 FR 10976). That document
listed an NADA for which a withdrawal of approval (WOA) was not
intended and failed to remove all conditions of use associated with the
withdrawn NADAs. This correction is being made to improve the accuracy
of the animal drug regulations.
DATES: This correction is effective March 31, 2014.
FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for
Veterinary Medicine (HFV-6), Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855, 240-276-9019,
george.haibel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is correcting a document amending the
animal drug regulations to reflect the WOA of NADAs that appeared in
the Federal Register of February 27, 2014 (79 FR 10976). That document
listed an NADA for which a WOA was not intended and failed to remove
all
[[Page 17860]]
conditions of use associated with the withdrawn NADAs. This correction
is being made to improve the accuracy of the animal drug regulations.
In the preamble in rule FR Doc. 2014-02617 published on February
27, 2014 (79 FR 10976), make the following corrections:
On page 10976, in the second column, in the 4th line of the
``SUMMARY'' section, remove ``69'' and replace with ``68''.
On page 10977, appearing near the end of the page, ``Huvepharma AD,
5th Floor, 3A Nikolay Haitov Str., 1113 Sofia, Bulgaria, has requested
that FDA withdraw approval of the following 16 NADAs and 8 ANADAs'', is
corrected to read ``Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str.,
1113 Sofia, Bulgaria, has requested that FDA withdraw approval of the
following 15 NADAs and 8 ANADAs''; and on the same page in the table,
the entry ``013-461 3-NITRO (roxarsone)/AMPROL Plus (amprolium and
ethopabate).'' is removed. This rule does not meet the definition of
``rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ``particular
applicability.'' Therefore, it is not subject to the congressional
review requirements in 5 U.S.C. 801-808.
List of Subjects in 21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is
corrected by making the following correcting amendments.
PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
0
1. The authority citation for 21 CFR part 558 continues to read as
follows:
Authority: 21 U.S.C. 360b, 371.
Sec. 558.195 [Amended]
0
2. In Sec. 558.195, remove paragraph (e)(1)(vii).
Sec. 558.355 [Amended]
0
3. In Sec. 558.355, remove and reserve paragraph (b)(3).
0
4. In Sec. 558.635, revise paragraphs (d)(4)(v), (d)(4)(vi), and
(d)(4)(vii) to read as follows:
Sec. 558.635 Virginiamycin.
* * * * *
(d) * * *
(4) * * *
(v) Monensin as in Sec. 558.355.
(vi) Salinomycin as in Sec. 558.550.
(vii) Semduramicin as in Sec. 558.555.
Dated: March 25, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014-06994 Filed 3-28-14; 8:45 am]
BILLING CODE 4160-01-P
